Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (WO1998052553) METHODS FOR TREATMENT OF CONDITIONS ASSOCIATED WITH LACTOSYLCERAMIDE
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/1998/052553 International Application No.: PCT/US1998/009958
Publication Date: 26.11.1998 International Filing Date: 14.05.1998
Chapter 2 Demand Filed: 23.10.1998
IPC:
A61K 31/16 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
16
Amides, e.g. hydroxamic acids
Applicants:
JOHNS HOPKINS UNIVERSITY [US/US]; 720 Rutland Avenue Baltimore, MD 21205, US
Inventors:
CHATTERJEE, Subroto; US
Agent:
CORLESS, Peter, F. ; Dike, Bronstein, Roberts & Cushman 130 Water Street Boston, MA 02109, US
Priority Data:
08/998,26224.12.1997US
60/047,24921.05.1997US
Title (EN) METHODS FOR TREATMENT OF CONDITIONS ASSOCIATED WITH LACTOSYLCERAMIDE
(FR) PROCEDES DE TRAITEMENT D'ETATS ASSOCIES AU LACTOSYLCERAMIDE
Abstract:
(EN) The present invention includes methods for treatment and prophylaxis of diseases, post-surgical disorders and bacterial infections associated with lactosylceramide. The methods generally provide for administration for a mammal, particularly a human, of a therapeutically effective amount of a compound that inhibits UDPGal:GlcCer$g(b)1-$m(g)4 galactosylceramide (GalT-2). $i(In vitro) and $i(in vivo) assays for detecting compounds with therapeutic capacity to modulate GalT-2 are also provided.
(FR) La présente invention concerne des procédés de traitement et de prophylaxie de maladies, de troubles post-chirurgicaux et d'infections bactériennes associés au lactosylcéramide. Ces procédés consistent généralement à administrer à un mammifère, en particulier à un être humain, une quantité efficace, dans la perspective thérapeutique, d'un composé qui inhibe le UDPGal:GlcCer$g(b)1-$m(g)4galactosylcéramide (GalT-2). L'invention concerne également des dosages biologiques $i(in vitro) et $i(in vivo) permettant de détecter des composés qui, du point de vue thérapeutique, sont susceptibles de moduler le GalT2.
Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW
African Regional Intellectual Property Organization (ARIPO) (GH, GM, KE, LS, MW, SD, SZ, UG, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)
Also published as:
EP0996433JP2001526683 CA2290742AU1998076866